Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
US7189518B2 · kind B2 · utility
11Cited by
2References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2002 |
| Grant date | Mar 13, 2007 |
| Priority date | — |
| Expiry date | Dec 24, 2022 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/324
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.